Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients

Table 4

Multivariate analysis of clinicopathological variables of neutropenia.

Variables	Before propensity matching			After propensity matching
	OR	95% CI		OR	95% CI
Age	1.006	0.987–1.026	0.516	0.998	0.982–1.014	0.777
Chemotherapy regimens
1	1	—	—	1	—	—
2	0.592	0.336–1.045	0.071	0.580	0.361–0.931	0.024
3	3.853	2.245–6.614	0.000001	4.184	2.725–6.424	<0.0001
4	2.124	1.252–3.606	0.005	1.984	1.282–3.072	0.002
TNM stage
I	1	—	—	1	—	—
II	1.157	0.797–1.678	0.443	1.554	1.139–2.120	0.005
III and IV	2.029	0.989–4.164	0.054	1.683	0.952–2.967	0.073
Neoadjuvant chemotherapy	0.962	0.523–1.768	0.901	0.896	0.521–1.541	0.691
ER	1.134	0.600–2.144	0.698	0.932	0.556–1.561	0.789
PR	0.957	0.533–1.718	0.883	0.969	0.602–1.560	0.898
HER-2	0.962	0.599–1.546	0.873	1.090	0.722–1.645	0.682
Ki67	0.859	0.582–1.266	0.442	1.022	0.745–1.402	0.893
TCM treatment	0.607	0.400–0.923	0.019	0.741	0.554–0.992	0.044

Chemotherapy: 1: the chemotherapy regimens contain AC/EC (Adriamycin or epirubicin, Cyclophosphamide) and CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil). 2: the chemotherapy regimens contain TC (paclitaxel or docetaxel, Cyclophosphamide) and T (paclitaxel or docetaxel). 3: the chemotherapy regimens contain anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (paclitaxel or docetaxel, Cyclophosphamide, and Adriamycin or epirubicin); TA/TE (paclitaxel or docetaxel, Adriamycin or epirubicin). 4: the chemotherapy regimens contain anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or epirubicin, Cyclophosphamide); CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil), followed with T or TH (paclitaxel or docetaxel, Herceptin).